Moderna Announces JAMA Network Open Publication of Real-World Comparative Effectiveness Data for mNEXSPIKE (COVID-19 Vaccine, mRNA) in Adults Aged 65 Years and Older
Key Highlights
- ➤mNEXSPIKE showed 35.9% relative effectiveness versus Comirnaty against medically attended COVID-19
- ➤mNEXSPIKE showed 47.0% relative effectiveness versus Comirnaty against COVID-19 hospitalization
- ➤mNEXSPIKE showed 39.3% relative effectiveness versus Comirnaty against MACE hospitalization
- ➤Study included 294,499 matched U.S. Veterans aged 65 years and older
- ➤Observational design leaves residual confounding and limits broader generalizability
Expert Statements
Francesca Ceddia, Chief Medical Affairs Officer of Moderna
“These findings demonstrate differentiated real-world performance for mNEXSPIKE in older adults, including against COVID-19-associated hospitalization. This evidence further supports the role mNEXSPIKE can play in protecting older adults from the health consequences of COVID-19, while providing important insight into its performance in a population that remains particularly vulnerable to severe disease.”
Stefan Gravenstein, Professor of Medicine at Brown University and principal investigator of the study
“Older adults continue to face a substantial burden from COVID-19, and vaccination remains one of our most important tools to help protect this population. Studies like this can help clinicians and patients make informed vaccination decisions by providing a better understanding of how different vaccine options perform in real-world settings.”
CAMBRIDGE, MA / ACCESS Newswire / November 11, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the publication of results from a large real-world study evaluating the comparative effectiveness of mNEXSPIKE® (COVID-19 Vaccine, mRNA) and Comirnaty® (COVID-19 Vaccine, mRNA) among U.S. Veterans aged 65 years and older during the 2025-2026 respiratory virus season. The analysis, published in JAMA Network Open, included 294,499 matched participants in the U.S. Veterans Health Administration (VHA).
The study's primary outcome was medically attended COVID-19, including hospitalization, emergency room visits, urgent care, outpatient visits, and antiviral treatment. mNEXSPIKE was associated with 35.9% relative vaccine effectiveness against medically attended COVID-19 compared with Comirnaty (95% CI: 20.4%-49.7%). The study found that vaccination with mNEXSPIKE was associated with a 47.0% relative vaccine effectiveness against COVID-19-associated hospitalization compared with Comirnaty (95% CI: 5.4%-74.8%), and point estimates consistently favored mNEXSPIKE across all individual components of medically attended COVID-19.
Get started
Create a free account to read the full story.